TFA Therapeutics (RAJAF) Accounts Payables (2020 - 2025)

TFA Therapeutics has reported Accounts Payables for 5 years, with the latest figure at $365140.0 in Q4 2025.

• On a quarterly basis, Accounts Payables rose 32.24% year-over-year to $365140.0 in Q4 2025; TTM through Dec 2025 was $365140.0, a 32.24% increase from a year earlier, with the FY2025 full-year figure at $365140.0, up 32.24% from the prior year.
• Accounts Payables was $365140.0 for Q4 2025 at TFA Therapeutics, up from $276125.0 in the prior quarter.
• The five-year high for Accounts Payables was $1.4 million in Q3 2023, with the low at $111696.0 in Q4 2021.
• Average Accounts Payables over 4 years is $460934.4, with a median of $276125.0 recorded in 2024.
• The sharpest annual moves came in 2021 and 2025: Accounts Payables jumped 90709.76% in 2021, then soared 32.24% in 2025.
• Over 4 years, Accounts Payables stood at $111696.0 in 2021, then soared by 66.02% to $185434.0 in 2023, then soared by 48.91% to $276125.0 in 2024, then surged by 32.24% to $365140.0 in 2025.
• The last three Accounts Payables figures came in at $365140.0 (Q4 2025), $276125.0 (Q4 2024), and $185434.0 (Q4 2023), per Business Quant data.